GNOS PV02 + INO 9012
Alternative Names: GNOS-PV02; Neoantigen vaccine GNOS-PV02; Personalised neoantigen DNA vaccine GNOS-PV02; Personalised Neoantigen-based vaccine GNOS-PV02Latest Information Update: 16 Apr 2024
At a glance
- Originator Geneos Therapeutics
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 07 Apr 2024 Efficacy, adverse event and immunogenicity data from a phase I/II clinical trials in Liver cancer released byGeneos Therapeutics
- 05 Apr 2024 Geneos Therapeutics a phase III confirmatory trial for Liver cancer
- 05 Apr 2024 Pharmacodynamics, efficacy and adverse events data from the phase Ib/IIa GT-30 trial in Liver cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)